Mitchell Sorsby, MD
Endocrinology, Diabetes & Metabolism · Plano, TXNPI 1154375939
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $825,872 of the $945,211 with a category attached, or 87.4%. 59 manufacturers reported payments, led by Lilly USA, LLC at 48.1% of the total. Reporting peaked in 2019 at $304,950 and has fallen 74.8% since, to $76,759 in 2025. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,485 payments — averaging $380.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$455K
- Novo Nordisk$175K
- Sanofi-aventis U.S. LLC$91K
- Radius Health, Inc.$81K
- Amarin Pharma, Inc.$27K
- AstraZeneca$24K
- plus $92K from 53 others
What the payments were for
- Consulting fees$18,1952%
- Speaking & faculty fees$825,87287%
- Travel & lodging$72,0948%
- Food & beverage$28,8223%
- Education$1680%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$262,259
- TRULICITY$126,330
- Wegovy$88,797
- Saxenda$82,986
- Tymlos$78,249
- SOLIQUA 100/33$60,559
- JARDIANCE$49,565
- TOUJEO$49,506
- Vascepa$26,007
- FARXIGA$22,305
- INVOKANA$18,119
- STEGLATRO$16,204
- DEXCOM CGM$6,951
- CYCLOSET$6,326
- FreeStyle Libre$4,700
- AFREZZA$4,064
- QSYMIA$3,625
- DEXCOM G6 CGM SYSTEM$3,522
- t:slim X2 insulin pump$2,300
- t-slim insulin pump$2,200
How this compares
$945,211 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 87 | $122,857 |
| MounjaroTirzepatide | 84 | $104,289 |
| JardianceEmpagliflozin | 67 | $77,523 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $49,986 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $47,302 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 30 | $44,225 |
| TrulicityDulaglutide | 32 | $39,285 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 25 | $29,197 |
| VascepaIcosapent Ethyl | 34 | $28,111 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 16 | $23,471 |
| FarxigaDapagliflozin Propanediol | 14 | $17,477 |
| SynthroidLevothyroxine Sodium | 143 | $17,244 |
| Novolog FlexpenInsulin Aspart | 23 | $8,682 |
| JanuviaSitagliptin Phosphate | 13 | $8,306 |
| NovologInsulin Aspart | 13 | $6,611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $454,676 | $143,574116 claims |
| Novo NordiskOzempic, Novolog | $175,449 | $129,469100 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $13,895 | $106,72192 claims |
| AstraZenecaFarxiga | $23,687 | $17,47714 claims |
| AbbVieSynthroid | $741 | $17,244143 claims |
| MerckJanuvia | $16,801 | $8,30613 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $226 | $1,933132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Plano
- Rosemarie LajaraPlano$1.2M
- Heidi SheaPlano$186K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.